Program Learning Objectives
Describe the mechanisms of monoclonal antibodies and antibody-drug conjugates.
Summarize recent updates in the use of monoclonal antibodies and antibody-drug conjugates clinically.
Outline common toxicities with monoclonal antibodies and antibody-drug conjugates and their management.
The Advances in Cancer Immunotherapy™ (ACI) programs aim to reach practicing clinical oncologists, nurses, nurse practitioners, advanced practitioners, pharmacists, emergency physicians, and other allied health professionals who wish to learn the basic principles of cancer immunotherapy and the most up-to-date clinical data for these treatments, in a multitude of disease states/therapeutic areas, in order to inform and integrate into their own clinical practice. In-training oncologists and hospital administrators will also find the program beneficial.
Case Study Submission Information
As part of the program, registrants are encouraged to submit case studies for expert review during the case study panel concluding the program. If you are interested in taking advantage of this opportunity, please review and sign the linked case study guidelines, and return your case study and signed guidelines to email@example.com.